MDT Medtronic Plc

Medtronic Pledges Support to End Obesity Stigma

Medtronic Pledges Support to End Obesity Stigma

DUBLIN, March 03, 2020 (GLOBE NEWSWIRE) -- Coinciding with World Obesity Day, Medtronic further demonstrated its ongoing commitment to increasing patient access to quality care by taking the . This action aligns with a joint consensus statement on the causes and negative consequences of obesity bias published today in  by a team of experts led by Professor Francesco Rubino from King’s College London.

According to the , more than 650 million people worldwide are living with obesity, which is amplified by numerous factors, many of which are beyond an individual’s control. In supporting the pledge, Medtronic condemns the use of stigmatizing language, images, attitudes, policies, and weight-based discrimination, wherever they occur, and commits to:

  •  Treat individuals with overweight and obesity with dignity and respect; 
  •  Refrain from using stereotyping language, images and narratives;
  •  Encourage educational initiatives aimed at eradicating weight bias through dissemination of modern-day knowledge of obesity and body weight regulation; and
  •  Support initiatives aimed at preventing weight-based discrimination in the workplace, education, and healthcare settings.

The pledge and international consensus statement renouncing obesity bias supports a growing body of scientific evidence on biological, genetic and environmental contributors to obesity. Findings from the independent Obesity Attitudes, Stigma and Knowledge study (ASK) published today in  demonstrates that for people living with obesity, bias against them is pervasive. By participating in the pledge, Medtronic aims to foster greater understanding of obesity and related diseases across the care continuum, and help patients gain access to critical care by reducing weight-related stigma.

World Obesity Day

As a primary sponsor of , Medtronic is supporting the world’s leading obesity organizations by leading activities and events – including hospital open days, patient education engagements, HCP roadshows, media and social media campaigns, and roundtable events with policymakers – in more than 20 countries. These events will continue to raise awareness of the causes and impacts of obesity, and the need for greater access to evidence-based treatments across the globe.

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-



John Jordan

Public Relations

Ryan Weispfenning

Investor Relations

EN
04/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...

Medtronic, Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong product diversification, offset by its large payouts to shareholders.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch